Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Globus Medical (GMED) and DENTSPLY SIRONA (XRAY)
Stifel Nicolaus Sticks to Its Hold Rating for DENTSPLY SIRONA (XRAY)
Dentsply Sirona to Participate in Upcoming Investor Conferences
Dentsply Sirona Is Maintained at Neutral by Goldman Sachs
Dentsply Sirona Is Maintained at Neutral by Goldman Sachs
Goldman Sachs: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from neutral to neutral, and adjusted the target price from $34.00 to $30.00.
Goldman Sachs: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from neutral to neutral, and adjusted the target price from $34.00 to $30.00.
Goldman Sachs Maintains Neutral on Dentsply Sirona, Lowers Price Target to $30
Goldman Sachs analyst Nathan Rich maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and lowers the price target from $34 to $30.
Dentsply Sirona Is Maintained at Outperform by Evercore ISI Group
Dentsply Sirona Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Group: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $40.00 to $35.00.
Evercore ISI Group: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $40.00 to $35.00.
Earnings Call Summary | Dentsply Sirona(XRAY.US) Q1 2024 Earnings Conference
The following is a summary of the DENTSPLY SIRONA Inc. (XRAY) Q1 2024 Earnings Call Transcript:Financial Performance:DENTSPLY SIRONA reported Q1 2024 revenue of $953 million, a decline of 2.6% from th
Evercore ISI Group Maintains Outperform on Dentsply Sirona, Lowers Price Target to $35
Evercore ISI Group analyst Elizabeth Anderson maintains Dentsply Sirona (NASDAQ:XRAY) with a Outperform and lowers the price target from $40 to $35.
UBS Adjusts Price Target on Dentsply Sirona to $37 From $38, Maintains Buy Rating
Dentsply Sirona (XRAY) has an average outperform rating and a price target range of $27 to $42, according to analysts polled by Capital IQ. Price: 28.52, Change: +0.14, Percent Change: +0.49
Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Appear To Be Weighed Down
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and th
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Dentsply Sirona Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price by $1
DENTSPLY SIRONA: A Buy Rating With Positive Long-Term Growth Prospects Despite Short-Term Challenges
Challenging Growth and Market Pressures Lead to Hold Rating for DENTSPLY SIRONA
Dentsply Sirona Price Target Cut to $33.00/Share From $35.00 by Baird
Dentsply Sirona Price Target Cut to $33.00/Share From $35.00 by Baird
Dentsply Sirona Is Maintained at Buy by Needham
Dentsply Sirona Is Maintained at Buy by Needham
Needham Maintains Buy on Dentsply Sirona, Lowers Price Target to $36
Needham analyst David Saxon maintains Dentsply Sirona (NASDAQ:XRAY) with a Buy and lowers the price target from $42 to $36.
Needham: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from buy to buy rating, and adjusted the target price from $42.00 to $36.00.
Needham: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from buy to buy rating, and adjusted the target price from $42.00 to $36.00.
Dentsply Sirona Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 26.85% Needham $42 → $36 Maintains Buy 04/18/2024 44.47% Barrington Research $41 → $41 Maintain
No Data